G01N33/5091

PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.

SPERM STRATIFICATION

The present invention relates to a method for stratifying spermatozoa in a sample obtained from a subject, comprising assaying the spermatozoa for membrane integrity and assaying the spermatozoa for DNA fragmentation. Thereby the spermatozoa stratification method allows an analysis of defined sperm categories and the prediction whether or not the spermatozoa will be functional. Further, a kit is encompassed for performing the method of spermatozoa stratification.

T Cells That Respond To Patient Neoepitopes
20230236172 · 2023-07-27 · ·

Compositions and methods are presented that allow for detection and prediction of an immune response in a subject that is selected to receive or that has received a vaccine. In selected embodiments, whole blood is used as starting material to obtain both dendritic cells and T cells, and synthetic or recombinant polypeptide(s) are used that include an antigen of the vaccine. The dendritic cells are then exposed to the synthetic or recombinant polypeptide(s), and thusly exposed dendritic cells are combined with the T cells to generate antigen reactive T cells. For detection or quantification, the antigen reactive T cells are expanded in vitro prior to ELISPOT or FACS analysis. Advantageously, such systems and methods are especially suitable for ascertaining an immune response against cancer antigens following vaccination with an anti-cancer vaccine.

ASSESSING AND TREATING BIOLOGICAL AGING

Abstract: This document relates to methods and materials for assessing biological aging. For example, methods and materials that can be used to determine if a mammal (e.g., a human) has an advanced biological age, is at risk of developing one or more adverse outcomes (e.g., adverse outcomes associated with medical intervention at an advanced biological age) following a medical intervention, and/or is likely to be responsive to one or more senotherapeutic agents are provided herein. In some cases, methods and materials for using one or more senotherapeutic agents to improve one or more outcomes for a mammal following a medical intervention (e.g., surgery) are also provided.

BOVINE EMBRYO EVALUATION USING AI/ML ANALYSIS OF REAL-TIME FRAME SPEED VIDEO FOR PREDICTING FEMALE-SEX OFFSPRING

A computer-implemented system and method for predicting female sex bovine offspring to result from a bovine embryo by processing video image data of the embryo. The method includes receiving image data derived from video of a target embryo taken at substantially real-time frame speed during an embryo observation period of time. The video contains recorded morphokinetic movement of the target embryo occurring during the embryo observation period of time. The movement is represented in the received image data and the received image data is processed using a model generated utilizing machine learning and correlated embryo outcome data.

Blood cell biomarker for late onset Alzheimer's disease
11567078 · 2023-01-31 · ·

Described herein are compositions and methods for diagnosing late-onset Alzheimer's disease (LOAD), treating LOAD and assessing efficacy of therapeutic agents used to treat LOAD.

INDUCTION OF REGULATORY B CELLS FOR THE TREATMENT OF IMMUNE-MEDIATED DISEASES
20230025756 · 2023-01-26 ·

The present invention contemplates that complement receptor 1 and 2 may play a role in the induction of regulatory B cells under inflammatory conditions that accompany immune-mediated diseases. For example, long noncoding RNA may regulation transcription of the complement receptor I gene, thereby resulting in an induction and/or suppression of regulatory B cells. Such long noncoding RNA in mature B cells may be specifically targeted to modify complement receptor 1 levels and induce or suppress the generation of antigen-specific regulatory B cells, thereby modifying the course of immune mediated diseases including, but not limited to, autoimmune disease, cancer, and infection.

METHOD FOR DIAGNOSING CUTANEOUS T-CELL LYMPHOMA DISEASES

The present invention relates to a method for diagnosing Sézary syndrome or mycosis fungoides in a subject. The present invention further relates to a method for determining the frequency of Sézary signature cells and/or mycosis fungoides cells in a sample. Further, the present invention relates to a computer-implemented method comprising a classifier algorithm to determine the frequency of Sézary signature cells and/or mycosis fungoides cells. In addition the present invention relates to a panel of biomarkers that can be used for the diagnosis of Sézary syndrome or mycosis fungoides.

T CELL PERFORMANCE ASSAY AS A PROGNOSTIC FACTOR FOR CLINICAL OUTCOME

The present disclosure provides, inter alia, compositions and methods for harnessing the immune system (e.g., T cells) as a detection tool to diagnose and predict cancer patient treatment outcomes and for monitoring the persistence of functional, non-genetically modified, T cell therapies in vivo after administration to a subject.

IDENTIFICATION OF HEALTH STATUS IN THE ELDERLY USING IMMUNOLOGICAL BIOMARKERS

A method for determining the health status of an elderly individual by testing the sample extracted from the individual for the presence of biomarkers, the bio markers being autoantibodies to antigens comprising MAPK13, CD96, FKBP3, PPM1A, PHLDA1, GLRX3, FEN1 and AURKA, wherein the antigens may further comprise one or more of UBE2I, AAK1, YARS, ASPSCR1, CASP10, FHOD2, TCL1A and MAP4, wherein PHLDA1 and CD96 correspond to healthy, AURKA, FEN1, CASP10 and AAK1 correspond to intermediate health, and UBE2I, YARS, ASPSCR1, FHOD2, TCL1A, MAP4, MAPK13, FKBP3, PPM1A and GLRX3 correspond to unhealthy.